Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

A bill that would ban the use of mRNA vaccines, including for Covid-19, is on its way to the House floor after passing out of committee in a party-line vote Wednesday. Sponsored by Rep. Greg Kmetz, ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

WASHINGTON, DC – Two Indian Americans, Yale Law School professor Natasha Sarin and surgical oncologist Dr. Vinod Balachandran ...

University of Queensland researchers have for the first time introduced genetic material into plants via their roots, opening ...

Moderna's Q4 earnings due Feb 14: analysts predict revenue decline & $2.73 loss. Explore vaccine demand, pipeline prospects, and stock outlook.

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

That’s thanks to a major philanthropic commitment from Sarasota’s Brian and Sheila Jellison Family Foundation. As the first ...

Young, a music teacher, met the King at UCLH last year while taking part in the first personalised trial of the mRNA vaccine for melanoma - the most dangerous form of skin cancer. He had invited the ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ...